Zacks Investment Research on MSN
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
AbbVie ABBV expects to return to robust revenue growth in 2025, despite the U.S. loss of exclusivity (LOE) for its flagship ...
(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction thanks ...
Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie's Humira are plummeting as the once-top-selling drug fights ...
AbbVie Inc. (NYSE:ABBV) is one of the best conservative stocks to buy now. On September 23, the company’s subsidiary, ...
Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...
AbbVie’s popular arthritis drug Humira is a powerhouse, producing $14 billion in annual sales to make up 60 percent of the drugmaker’s revenue. However, generic versions of the drug are around the ...
Jan 3 (Reuters) - CVS Health CVS.N said on Wednesday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April ...
Even at a steep discount, the list prices of new adalimumab biosimilars are significantly higher than the original price of the originator product (Humira), highlighting how dramatically its list ...
FILE - Packaging for AbbVie's drug, Humira, is photographed in Houston on July 18, 2014. Patients who take the autoimmune disease treatment may see some price relief when several lower-cost, ...
The pharmacy benefit manager SmithRx has announced that through a partnership with the Mark Cuban Cost Plus Drug Company, it will offer Yusimry, an adalimumab biosimilar, for less than 90% of the cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback